Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 15Active not recruiting 8Terminated 5Withdrawn 3Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 21fludarabine 17Specimen Handling 13Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 9Radiotherapy 7Cisplatin 7fludarabine phosphate 5Injections 5tislelizumab 4daratumumab 4Rituximab 4Paclitaxel 4Ipilimumab 4Interleukin-2 4Immune Checkpoint Inhibitors 4Gemcitabine 4Fluorouracil 4Drug Therapy 4Doxorubicin 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3toripalimab 3X-Rays 3Radiosurgery 3Platinum 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × auricularum × Clear all
NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡